Effect of Metoclopramide on the duration of spontaneous active phase of labor in primigravid women at the Jos University Teaching Hospital; a randomized, double blind, placebo controlled trial
- Conditions
- Labour
- Registration Number
- PACTR202401879224913
- Lead Sponsor
- Jos University teaching Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 88
1.Primigravidae at term with singleton pregnancy
2.Primigravidae at term with spontaneous onset of labour and foetus in longitudinal lie and cephalic presentation
3.Primigravidae at term with cervical os dilatation of 4cm
4.Primigravidae meeting the above criteria who give consent to be included in the study
1.Women who have had a previous delivery
2.Women who have progressed beyond 4cm cervical os dilatation
3.Women with any contraindication to vaginal delivery
4.Women with abnormal presentations, multiple pregnancies, cephalo-pelvic disproportion, maternal obesity, short stature or medical disorder in pregnancy
5.Women with previous uterine scars
6.Women with previous adverse drug reaction to metoclopramide or with contraindication to metoclopramide
7.Women taking medications with drug interaction to metoclopramide
8.Women presenting preterm in labour
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome measures will include the total duration of the first, second and third stages of labor and cervical dilatation rate
- Secondary Outcome Measures
Name Time Method eed for oxytocin augmentation, delivery route, clinical maternal side effects (particularly tardive dyskinesia, drowsiness, restlessness, breast enlargement, low mood, diarrhoea, and urinary incontinence), perineal tears and postpartum blood loss. Other secondary outcomes include APGAR scores at minute one and five after birth as well as neonatal intensive care unit admission rates.